Skip to main content
Addgene
Showing: 841 - 860 of 53133 results

  3. SARS-CoV-2 Spike (S) Receptor Binding Domain (RBD) library N501Y Tile 2 (positions 437-527)

    Pooled Library
    #174296
    Purpose
    This library contains mutations to SARS-CoV-2 Spike RBD N501Y variant in which all surface exposed residues on S RBD (Tile 2, positions 437-527) were mutated to every other amino acid.
    Depositor
    Timothy Whitehead
    Article
    Francino-Urdaniz et al Cell Rep. 2021 Aug 31;36(9):109627. doi:
    Expression
    Yeast
    Available since
    Sept. 13, 2021
    Availability
    Academic Institutions and Nonprofits only

  4. SARS-CoV-2 Spike (S) Receptor Binding Domain (RBD) library N501Y Tile 1 (positions 333-436)

    Pooled Library
    #174295
    Purpose
    This library contains mutations to SARS-CoV-2 Spike RBD N501Y variant in which all surface exposed residues on S RBD (Tile 1, positions 333-436) were mutated to every other amino acid.
    Depositor
    Timothy Whitehead
    Article
    Francino-Urdaniz et al Cell Rep. 2021 Aug 31;36(9):109627. doi:
    Expression
    Yeast
    Available since
    Sept. 13, 2021
    Availability
    Academic Institutions and Nonprofits only

  5. SARS-CoV-2 Spike (S) Receptor Binding Domain (RBD) library E484K Tile 2 (positions 437-527)

    Pooled Library
    #174294
    Purpose
    This library contains mutations to SARS-CoV-2 Spike RBD E484K variant in which all surface exposed residues on S RBD (Tile 2, positions 437-527) were mutated to every other amino acid.
    Depositor
    Timothy Whitehead
    Article
    Francino-Urdaniz et al Cell Rep. 2021 Aug 31;36(9):109627. doi:
    Expression
    Yeast
    Available since
    Sept. 13, 2021
    Availability
    Academic Institutions and Nonprofits only

  6. SARS-CoV-2 Spike (S) Receptor Binding Domain (RBD) library E484K Tile 1 (positions 333-436)

    Pooled Library
    #174293
    Purpose
    This library contains mutations to SARS-CoV-2 Spike RBD E484K variant in which all surface exposed residues on S RBD (Tile 1, positions 333-436) were mutated to every other amino acid.
    Depositor
    Timothy Whitehead
    Article
    Francino-Urdaniz et al Cell Rep. 2021 Aug 31;36(9):109627. doi:
    Expression
    Yeast
    Available since
    Sept. 13, 2021
    Availability
    Academic Institutions and Nonprofits only

  8. pAAV.GFAP.Cre.WPRE.hGH (AAV PHP.eB)

    Viral Prep
    #105550-PHPeB
    Purpose
    Ready-to-use AAV PHP.eB particles produced from pAAV.GFAP.Cre.WPRE.hGH (#105550). In addition to the viral particles, you will also receive purified pAAV.GFAP.Cre.WPRE.hGH plasmid DNA. GFAP-driven expression of Cre. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.
    Depositor
    James M. Wilson
    Promoter
    GFAP
    Tags
    None
    Available since
    July 28, 2020
    Availability
    Academic Institutions and Nonprofits only

  9. pAAV.CMV.PI.EGFP.WPRE.bGH (AAV PHP.eB)

    Viral Prep
    #105530-PHPeB
    Purpose
    Ready-to-use AAV PHP.eB particles produced from pAAV.CMV.PI.EGFP.WPRE.bGH (#105530). In addition to the viral particles, you will also receive purified pAAV.CMV.PI.EGFP.WPRE.bGH plasmid DNA. CMV-driven EGFP control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.
    Depositor
    James M. Wilson
    Promoter
    CMV
    Tags
    EGFP
    Available since
    Feb. 16, 2024
    Availability
    Academic Institutions and Nonprofits only

  10. pENN.AAV.EF1a.eGFP.WPRE.rBG (AAV PHP.eB)

    Viral Prep
    #105547-PHPeB
    Purpose
    Ready-to-use AAV PHP.eB particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.
    Depositor
    James M. Wilson
    Promoter
    EF1a
    Tags
    EGFP
    Available since
    Feb. 16, 2024
    Availability
    Academic Institutions and Nonprofits only
Showing: 841 - 860 of 53133 results